文献速递临床试验与 GCP流行病学与生物统计

利益相关方映射与参与在蒙古STREAM耐多药结核临床试验实施中的作用

The role of stakeholder mapping and engagement in Mongolia during the implementation of the STREAM clinical trial for MDR-TB.
PubMed 文献 · Trials · 2025-05-29

本文描述蒙古站点在STREAM III期耐多药结核临床试验中的利益相关方参与工作,依据PCORI框架评估。参与活动与互惠关系、共同学习、建立伙伴关系、透明诚信信任原则高度一致,促成98%保留率和全站点最高招募量;作者建议低资源地区试验站点扩大利益相关方范围、开展能力建设并规划社区参与的长期可持续性。

要点

  • 蒙古站点在STREAM试验全阶段开展利益相关方参与,与PCORI参与原则高度一致。
  • 参与活动包括与国家结核病规划持续沟通、社区参与项目、心理社会支持及社区顾问委员会参与评估。
  • 上述活动促成98%保留率和全STREAM站点最高参与者招募量。

核心结论

  • 通过利益相关方协作可取得显著且可持续的收益。
  • 作者建议低资源地区试验站点在规划参与时对相关利益相关方采取 expansive 视角,开展能力建设与知识共享,规划社区参与的长期可持续性,围绕具体目标设计参与,定制并优化沟通策略,并设计涉及关键政策制定者的利益相关方参与。

研究设计与样本

  • 本文描述蒙古站点在STREAM III期临床试验(评估耐多药结核新治疗方案)实施期间的利益相关方参与工作,并依据PCORI rubric进行评估。

主要发现

  • 参与活动与PCORI的互惠关系、共同学习、建立伙伴关系以及透明、诚实和信任原则高度一致。
  • 规划阶段与民间社会组织建立关键伙伴关系共同领导试验,开展利益相关方映射并制定整体参与策略。
  • 实施阶段开展确保研究可行性、改善招募、确保研究活力及确保利益相关方参与真实性/价值的活动。
  • 活动包括与国家结核病规划持续沟通以确保转诊潜在试验参与者、实施全面社区参与项目、与伙伴合作提供心理社会支持、能力建设与知识共享、定期沟通试验进展以及社区顾问委员会参与社区参与评估。
  • 上述活动促成98%的保留率和全STREAM试验站点中最高的参与者招募量。

关键数值与推荐

  • 保留率98%。
  • 参与者招募量为全STREAM试验站点中最高。

临床怎么用

  • 作者建议低资源地区的试验站点在规划参与时对相关利益相关方采取 expansive 视角。
  • 作者建议开展能力建设与知识共享。
  • 作者建议规划社区参与的长期可持续性。
  • 作者建议围绕具体目标设计参与。
  • 作者建议定制并优化沟通策略,并设计涉及关键政策制定者的利益相关方参与。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials evaluating new regimens for multidrug-resistant tuberculosis (MDR-TB) are typically conducted in multiple countries because global registration of new TB drugs requires evaluation in diverse populations. The complexity of multi-site trials makes implementation challenging, especially in lower-resource settings, where the burden of MDR-TB is highest. Stakeholder engagement can improve trial implementation and outcomes. Here, we describe the Mongolia site's stakeholder engagement during STREAM, a phase III clinical trial evaluating novel treatment regimens for MDR-TB. MAIN BODY: We assessed our stakeholder engagement against the PCORI rubric. Engagement at all phases of the trial aligned well with the PCORI engagement principles of reciprocal relationships; co-learning; building partnerships; and transparency, honesty, and trust. In the planning phase, we formed a key partnership with a civil society organization to co-lead the trial, undertook stakeholder mapping, and developed an overall engagement strategy. During trial implementation, we undertook activities aimed at ensuring feasibility of the study, improving recruitment, ensuring viability of the study, and ensuring authenticity/value of stakeholder engagement. Activities, which included continuous communication with the national TB program to ensure referral of potential trial participants, implementation of a comprehensive community engagement (CE) program, delivery in collaboration with partners of psychosocial support for trial participants, capacity-building and knowledge sharing, regular communications on trial developments and progress, and community advisory board (CAB) participation in CE assessment, contributed to achieving a 98% retention rate and the highest participant recruitment across all STREAM trial sites. In the dissemination phase, CAB members worked together with the site and sponsor to ensure strategies and materials were tailored to stakeholders' needs, including participants; communities; frontline healthworkers; and national-level stakeholders. Stakeholder participation in research and in improving routine TB care in the country has been sustained since completion of the trial. CONCLUSIONS: Significant and sustainable gains can be made through stakeholder collaboration. We recommend that trial sites in lower-resourced settings take an expansive view of relevant stakeholders when planning engagement; undertake capacity-building and knowledge sharing; plan for long-term sustainability of CE; design engagement around specific objectives; tailor and optimize communication strategies; and design stakeholder engagement to involve key policy makers. TRIAL REGISTRATION: ISRCTN78372190 - Registration date is October 14, 2010 (Stage 1) and ISRCTN18148631 - Registration date is February 10, 2016 (Stage 2).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tsogt B, Gurumurthy M, Giallongo E, et al. The role of stakeholder mapping and engagement in Mongolia during the implementation of the STREAM clinical trial for MDR-TB. Trials. 2025. PMID: 40442716. doi:10.1186/s13063-025-08887-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。